Moutsopoulos H M, Gallagher J D, Decker J L, Steinberg A D
Arthritis Rheum. 1978 Sep-Oct;21(7):798-802. doi: 10.1002/art.1780210710.
In the context of prospective trials of immunosuppressive drugs in systemic lupus erythematosus (SLE) nephritis, 83 patients were studied with regard to development of herpes zoster. Herpes zoster was found to occur with high frequency (21%) in patients with SLE nephritis treated with immunosuppressive agents. The course of herpes zoster was benign: no deaths occurred and only 2 of the 18 patients developed generalized disease, which resolved without sequelae. Specific antiviral therapy was not necessary and there appears to be no need to decrease immunosuppressive medications. Zoster occurred when the SLE was relatively inactive and did not exacerbate the SLE. No statistical difference in the incidence of zoster was found among the patient groups treated with different immunosuppressive regimens.
在系统性红斑狼疮（SLE）肾炎免疫抑制药物的前瞻性试验背景下，对83例患者进行了带状疱疹发病情况的研究。发现接受免疫抑制剂治疗的SLE肾炎患者中带状疱疹的发生率很高（21%）。带状疱疹病程呈良性：无死亡病例，18例患者中仅有2例发展为全身性疾病，且痊愈后无后遗症。无需进行特异性抗病毒治疗，似乎也无需减少免疫抑制药物的用量。带状疱疹在SLE相对不活跃时发生，且未加重SLE病情。不同免疫抑制方案治疗的患者组之间带状疱疹的发生率无统计学差异。
